RMD share price in focus
Founded in 1989 by Peter Farrell in Australia, ResMed is now headquartered in San Diego, California. The company specializes in medical equipment, offering cloud-connectable continuous positive airway pressure (CPAP) machines to treat obstructive sleep apnea (OSA). Although ResMed is based in the US, its shares are listed on both the NYSE and the ASX.
With over 10,000 employees and operations in more than 140 countries, ResMed has two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS). In the Sleep and Respiratory Care unit, ResMed provides top-of-the-line CPAP machines for sleep apnea, along with non-invasive and invasive ventilation solutions for life-support patients. In the SaaS unit, the company offers software that supports durable medical equipment (DME/HME), which plays a key role in out-of-hospital care.
ResMed’s extensive digital health network, powered by its cloud-connected devices, enables the company to use its industry-leading hardware (such as masks and humidifiers) and SaaS data to generate valuable insights, enhance patient outcomes, and lower overall healthcare costs.
The appeal of ASX Healthcare shares
The S&P/ASX200 Healthcare Index (ASX: XHJ) has returned 1.51% per year over the last 5 years compared to 3.75% per year from the broader ASX 200. Here are three key reasons to consider adding a healthcare company like RMD to your investing watchlist.
Sticky revenue
Healthcare spending (in most cases) is essential spending, making it one of the last areas people cut back on during tough economic times.
Unlike cyclical businesses affected by commodity prices or seasonal demand, healthcare companies benefit from stable and consistent revenue streams. We sometimes call this ‘sticky’ revenue. Evidence of this fact is that healthcare was the best performing sector during the GFC.
Growth potential
Global healthcare spending, particularly in the US – which accounts for over 40% of the global total – is projected to grow significantly. Estimates for US growth are 7% per year from 2022 to 2027, reaching US$819 billion.
Within the broad sector of healthcare, certain sub-sectors stand out for their additional growth potential. For example, healthcare IT, data solutions, and ‘software-as-a-service’ (or SaaS) companies are forecast to grow at more than 15% per year from 2024 to 2030, a rate that would get most investors interested.
The ethical investor
A recent Morgan Stanley survey revealed that more than half of investors plan to increase their allocation to sustainable investments in 2024. With growing interest in ‘ethical’ and ‘sustainable’ investing, sectors like healthcare that provide essential public services are well-positioned to attract new capital and investors.
RMD share price valuation
The S&P/ASX200 Consumer Discretionary Index (ASX: XDJ) has generated returns of 1.51% per year over the last 5 years. That’s compared to 3.75% per year from the broader ASX 200. The consumer discretionary sector covers a wide range of goods and services, so it can be hard to compare companies in this group. However, there are a few things you might want to consider when investing in a consumer discretionary company like RMD.
Economic environment
Consumer discretionary companies usually experience their best performance when interest rates are low. It’s fairly intuitive – when interest rates are low, you’re more likely to go out and buy those ‘nice-to-haves’ or things that you may not really need, but you certainly want. That could be the latest iPhone, a European vacay or that Ryobi power drill you’ve always wanted – it all comes under this category.
Despite the current high interest rate environment, RMD has still managed to grow revenue by 13.6% per year over the last three years.
Dividends
The dividends you’ll receive can vary with the current economic environment, but historically many of the big ASX consumer discretionary shares have been reliable dividend payers.
RMD offers a current dividend yield of 0.8% and over the last 5 years has averaged 0.9%.
Familiarity
We often hear the mantra, ‘invest in what you know’. If you take that to heart, consumer discretionary companies could make a lot of sense. These companies tend to be household names and brands you see everyday.
You probably have a better idea how Resmed CDI make their money then some niche tech company or a B2B industrials company. This doesn’t necessarily mean performance will be any good, but they’re definitely easier to get your head around when you’re new to investing.
